FREMONT, Calif., May 12 /PRNewswire-FirstCall/ -- Curon Medical, Inc. today announced that Larry C. Heaton II, President and Chief Executive Officer, will present at the Robins Emerging Opportunities Investment Conference at the University Club in New York City on Wednesday, May 17, 2006 at 10:15 a.m. ET.
(Logo: http://www.newscom.com/cgi-bin/prnh/20050318/CURONLOGO )
A live webcast of the presentation can be accessed at http://www.investorcalendar.com/CEPage.asp?ID=104601 and through the Company’s website at www.curonmedical.com. The webcast will be archived for two weeks.
About Curon Medical, Inc.
Curon Medical develops, manufactures and markets innovative proprietary products for the treatment of gastrointestinal disorders. The Company’s products and products under development consist of radiofrequency generators and single use disposable devices. Its first product, the Stretta System, received U.S. Food and Drug Administration clearance in April 2000 for the treatment of gastroesophageal reflux disease, commonly referred to as GERD. The Company’s Secca System for the treatment of bowel incontinence received clearance from the FDA in March 2002. For more information on the Company or its products, please visit the company’s website at http://www.curonmedical.com
About the Stretta(R) System
Curon’s proprietary Stretta System provides physicians with the tools to perform a minimally invasive, outpatient endoscopic procedure for the treatment of GERD. The Stretta System consists of the Stretta Catheter, which is a disposable, flexible catheter and the Curon Control Module. Using the Stretta System, the physician delivers temperature-controlled radiofrequency energy to create thermal lesions in the muscle of the lower esophageal sphincter (LES). The tissue response to radiofrequency delivery alters LES function, which results in statistically significant improvements in GERD symptom scores, reduction in acid exposure and reduction in anti-secretory medication requirement.
About the Secca(R) System
The Secca System provides physicians with devices to perform a minimally invasive outpatient procedure for the treatment of bowel incontinence in patients who have failed more conservative therapy such as diet modification and biofeedback. The Secca System utilizes the same technology and treatment concepts as the Stretta System. Using the Curon Control Module and the Company’s Secca disposable handpiece, physicians deliver radiofrequency energy into the muscle of the anal sphincter to improve its barrier function.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20050318/CURONLOGO /AP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comCuron Medical, Inc.
CONTACT: Larry C. Heaton II, President and Chief Executive Officer,+1-510-661-1801; or Investor Relations: Melody A. Carey of RxCommunications Group, LLC, +1-917-322-2571
Web site: http://www.curonmedical.com//
